Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Looking Ahead To The Potentially Game Changing TESARO Inc (TSRO) Data

TESARO Inc (NASDAQ:TSRO) just announced that the FDA has granted Fast Track designation to its lead ovarian, fallopian tube, or primary peritoneal cancer candidate, and that on the back of the designation, the company has commenced the submission of a rolling New Drug Application (NDA) for the drug.

As is the nature of a rolling submission, we don’t yet have complete clarity on the data that will underpin the final submission. However, the full presentation is set for October, and at that point, we should get some pretty solid insight into the drug’s chances of approval come expedited PDUFA.

Ahead of the presentation, therefore, let’s take a look at the drug in question, and figure out what we want to see from the data as indicative of a successful commercialization push.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

Here goes.

The drug in question is called niraparib, and as mentioned, it’s targeting a host of reproductive organ related cancers in females. Primarily, and likely to be the main revenues driver on approval, is the ovarian cancer target indication. The drug is part of a family of investigative candidates called PARP inhibitors. We’ve covered this type of compound on a number of occasions in the past, but by way of a quick reintroduction, they are designed to stop the DNA reparation action of an enzyme called poly ADP ribose polymerase, the PARP in the drug’s descriptive title. When cells replicate, the DNA that controls the process becomes damaged in the newly formed cell. The damage isn’t massive, but if left unchecked, the damage builds up and can seriously impact replication after a number of phases. The PARP enzyme is responsible for fixing the damage, post-replication.

Cancerous cells are highly susceptible to this type of damage. They replicate far quicker and for more than healthy cells, and so the cumulative damage can quickly become transcription-prohibitive. Of course, this is a good thing in cancerous cells. However, the PARP enzyme works to fix the damage, facilitating reproduction and proliferation.

By inhibiting the PARP enzyme niraparib stops it from repairing the DNA in cancerous cells, and in turn, slows (and eventually halts) cancer cell proliferation. The cells that do make it eventually die out through the natural apoptosis process (or by way of a concurrent SOC treatment – chemo, for example).

That’s the theory, and there’s a pretty solid body of evidence in favor of the positive hypothesis. Further, this data isn’t just limited to studies carried out by TESARO Inc (NASDAQ:TSRO). A number of companies in the space, big and small, are working on this type of therapy, and each has added to a growing efficacy base.

What are we looking for from the upcoming data presentation as indicative of success come PDUFA for niraparib?

The primary endpoint for the trial is progression free survival, and the trial is double blinded against a placebo arm. This blinding makes interpretation pretty simple – we are looking for a stat sig (by stat sig we mean we are looking for a p-value of less than 0.05) difference between progression free survival in the active arm than the placebo arm. It’s a 35-month cycle, and dosing is continuous across a 28-day period, randomized 2:1 in favor of the active arm.

Secondary endpoints will play into interpretation as various kickers, with overall survival across the 35-month period and patient reported outcomes (basically another way of saying safety and tolerability) being the ones we are watching the closest. As a brief side note on PARP inhibitors, safety hasn’t really been too much of an issue to date, and so we expect it not to inhibit any potential approval from the agency when decision day comes. The generally poor prognosis of ovarian cancer (especially in the platinum resistant patients that this trial is focusing on) and the pretty rough safety profile of current SOC (chemotherapy and radiation) compounds this bias.

As a final note, it’s worth mentioning that big pharma incumbent Gilead Sciences, Inc. (NASDAQ:GILD) suggested recently it might be interested in picking up a PARP inhibitor near term, if it can find the right candidate. TESARO Inc (NASDAQ:TSRO)’s late stage asset looks to fit the criteria for a potential asset acquisition, and both the potential, and the realization of this potential, could attract buy volume in the coming months.

The data is set for presentation at the Presidential Symposium session at the European Society for Medical Oncology (ESMO) congress, so October 8 is the date to watch.

Follow Tesaro Inc. (NASDAQ:TSRO)
Trade (NASDAQ:TSRO) Now!

Note: This article is written by Mark Collins and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!